Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is indicated for selected patients with peritoneal surface malignancies like primary peritoneal, appendiceal, colorectal, gastric or ovarian cancers that have spread within the abdominal cavity. Patients with limited or manageable extra-abdominal disease burden, good performance status, and favorable tumor biology are ideal candidates. CRS-HIPEC aims to remove visible tumors and eradicate microscopic disease, improving outcomes and potentially offering long-term survival benefits. However, careful patient selection and multidisciplinary evaluation are essential to optimize treatment success and minimize risks associated with this complex surgical procedure.
This is a supra major Surgery done at highly specialized centers wherein all the Cancerous tissues are resected and heated Chemotherapy drug is perfused directly to the peritoneum. Hyperthermic intraperitoneal chemotherapy (HIPEC) surgery demands a highly skilled and experienced team comprising Gastrooncosurgeons, anesthesiologists, intensivists, nutritionists, nurses, and perfusionists. Expertise in cytoreductive surgery (CRS) is crucial to meticulously excise tumors, while proficiency in delivering heated chemotherapy ensures efficacy and safety. The team must collaborate seamlessly, managing intraoperative challenges and potential complications.
The CRS HIPEC proceedure involves removal of all cancerous tissue from the abdomen and perfusion by chemotherapy medicine, which is heated and circulated using a specialized machine.
A better life starts with better health